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First case of amebic liver abscess 22 years after the first
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Abstract – A 72-year-old man consulted in November 2012 for abdominal pain in the right upper quadrant. The
patient had a history of suspected hepatic amebiasis treated in Senegal in 1985 and has not traveled to endemic areas
since 1990. Abdominal CT scan revealed a liver abscess. At first, no parasitological tests were performed and the
patient was treated with broad-spectrum antibiotics. Only after failure of this therapy, serology and PCR performed
after liver abscess puncture established the diagnosis of hepatic amebiasis. The patient was treated with metronidazole
and tiliquinol-tilbroquinol. Amebic liver abscess is the most frequent extra-intestinal manifestation. Hepatic amebiasis
22 years after the last visit to an endemic area is exceptional and raises questions on the mechanisms of latency and
recurrence of these intestinal protozoan parasites.
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Résumé – Premier cas d’abcès amibien du foie 22 ans après la première occurrence. Un homme de 72 ans
consulte en novembre 2012 pour des douleurs abdominales dans le quadrant supérieur droit. Le patient présente
un antécédent probable d’abcès amibien du foie traité en 1985 au Sénégal et n’a pas voyagé en région d’endémie
depuis 1990. Le scanner abdominal réalisé met en évidence un abcès hépatique. Dans un premier temps, aucun
examen parasitologique n’est effectué et le patient est traité par des antibiotiques à large spectre. Suite à l’échec
de ce traitement, la sérologie et la PCR réalisées après ponction de l’abcès hépatique, établissent le diagnostic
d’amibiase hépatique. Le patient est traité par métronidazole et tiliquinol-tilbroquinol. L’abcès amibien du foie est
la manifestation extra-intestinale de l’amibiase la plus fréquente. L’amibiase hépatique 22 ans après le dernier
voyage en zone d’endémie est exceptionnelle et soulève des questions concernant les mécanismes de latence et de
récurrence des protozoaires intestinaux.
Introduction
Entamoeba histolytica, an amebozoan parasite specific to
humans, is the causative agent of human amebiasis, endemic
in most tropical and subtropical countries. Amebic colitis
and liver abscess (ALA) are the most frequent intestinal and
extra-intestinal manifestations [25]. The majority of patients
develop ALA within 5 months following travel to endemic
areas, but some cases with a prolonged latency period have
been described (up to 32 years) [11, 28].
E. histolytica infection occurs when mature cysts are
ingested, mainly from fecally contaminated water and/or food,
most frequently in the developing world. ALA is caused by
hematogenous spread of trophozoites from intestinal mucosa
to the liver through the portal vein. Even though various
organs, such as the brain, liver, and lungs, can be affected by
extra-intestinal amebiasis, liver abscess is the most frequent
manifestation. The clinical symptoms of ALA include fever,
weight loss, dull and aching abdominal pain in the right upper
quadrant and hepatomegaly [2, 29]. Rupture of abscess and
dissemination in the pleural, peritoneal, or pericardial cavities
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are the major complications [25]. Diagnosis of ALA is
typically based on the clinical symptoms, characteristic of
radiological imaging and serology. Diagnosis can be confirmed
by PCR detection of E. histolytica DNA in the abscess fluid
[29]. The general recommendation for treating invasive
amebiasis is the combination of a tissue amebicide (principally
metronidazole) with a luminal amebicide to eliminate any
surviving parasites in the colon [9, 27]. Some cases of relapse
of ALA have been described even with appropriate treatment
[13, 21]. Despite its medical importance, there is a consider-
able lack of knowledge about the epidemiology of this
infection. Forty million people are infected annually,
although these estimations are skewed by the inclusion of
the morphologically identical but non-pathogenic species
Entamoeba dispar. E. histolytica causes up to 100,000 deaths
per year, placing amebiasis second only to malaria in
terms of mortality due to protozoan parasites [26]. France is
not an endemic region for amebiasis, but sporadic cases of
locally acquired infections have been reported [1, 15, 16].
Here, we report a case of amebic liver abscess relapse 22 years
after the first occurrence and without any travel to endemic
areas.
Case presentation
A 72-year-old man, residing in Eastern France (Alsace),
was admitted to the medical intensive care unit in October
2012 for acute calculous cholecystitis associated with severe
sepsis. No liver abscess was diagnosed at that time. He had a
history of suspected amebic liver abscess, operated and treated
by metronidazole, after a trip to Senegal in 1985. The last time
the patient traveled to endemic areas dates back to 1990,
i.e. the West Indies. In November 2012, a few days after his
release from the hospital, the patient consulted again for
abdominal pain in the right upper quadrant with an inflamma-
tory syndrome (C-reactive protein: 237 mg/L, procalcitonin:
71.2 ng/mL) without fever. Abdominal CT scan revealed a
liver abscess. A liver puncture sample sent to the bacteriology
laboratory was sterile. No parasitological sampling was con-
ducted. A broad-spectrum antibiotic treatment by vancomycin
(2 g/day), Tazocin (piperacillin/tazobactam) (12 g/day), and
metronidazole (1500 mg/day) was implemented for a period
of 3 weeks. Treatment with metronidazole was not continued
by the patient due to poor digestive tolerance.
In December 2012, the patient was again hospitalized in
the nephrology department for acute renal failure probably
related to drug toxicity due to trimethoprim/sulfamethoxazole
(creatinine: 360.4 lmol/L, urea: 14.3 mmol/L, Glomerular
Filtration Rate: 15 ml/min/1.73 m2).
At this time, the patient presented no biological inflamma-
tory syndrome (CRP: 7.6 mg/L) or liver anomalies (ASAT:
19 U/L, ALAT: 13 U/L, gammaGT: 47 U/L, PAL: 154 U/L,
total bilirubin: 7.4 lmol/L, conjugated bilirubin: 3.6 lmol/L)
and was apyretic. MR cholangiopancreatography revealed a
partitioned collection fluid (6.6 cm · 4 cm) in segments I
and II, and an abscess in segment VII (5.5 cm · 5 cm)
(Figs. 1–3).
Hydatid disease and alveolar echinococcosis serologies
(these larval cestodes being endemic in Eastern France) were
negative. However, amebiasis serology by ELISA Ridascreen
E. histolytica IgG, (R-Biopharm GmbH, Darmstadt, Germany)
was positive (IgG: 8.72; threshold: 0.9), as was latex agglutina-
tion (Bichro-Latex Amibe Fumouze, Fumouze Diagnostics,
Figure 1. Axial T2 weighted magnetic resonance cholangi-
opancreatography (MRC) images showing a voluminous and
heterogeneous collection in the left liver lobe (amoebic abscess).
Figure 2. Coronal T2 weighted MRC images showing a volumi-
nous and heterogeneous collection in the left liver lobe (amoebic
abscess).
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Levallois-Perret, France). In-house Entamoeba histolytica PCR
was performed on a puncture of the liver abscess. DNA was
extracted from 200 lL of the sample using the QIAamp
DNA Mini Kit (Qiagen, Courtaboeuf, France). PCR amplifica-
tion was carried out as described by Gonin and Trudel [8]
using HotStarTaq DNA Polymerase PCR Buffer 1X (Qiagen),
1 U HotStarTaq DNA Polymerase (Qiagen), 200 lM dNTPs,
1 mM MgCl2, and 0.5 lM of each primer ED1 + EDH2 for
the detection of Entamoeba dispar or EH1 + EDH2 for the
detection of Entamoeba histolytica. Cycling conditions were
as follows: 15 min incubation at 95 C followed by 40 cycles
consisting of 30 s at 95 C, 60 s at 51 C, and 40 s at 72 C,
with a final 5 min elongation at 72 C. The PCR was moni-
tored by positive and negative controls. This in-house PCR test
was positive, thus confirming the diagnosis of ALA.
Direct examination by microscopy and culture of the
aspirated liver abscess fluid were negative. The stool examina-
tion performed in this patient in January 2013 was also nega-
tive. The clinical course was favorable after 14 days of
metronidazole and 10 days of tiliquinol-tilbroquinol.
Discussion
Amebiasis occurs in 10% of the world’s population and
is most common in tropical and subtropical regions. ALA is
the most common extra-intestinal manifestation of amebia-
sis. ALA develops in less than 1% of patients infected with
E. histolytica. The disease should be suspected in anyone with
a history of residency in or travel to an endemic area associated
with fever, right upper quadrant pain, and significant hepatic
tenderness [22]. In Europe, ALA is observed in European-born
travelers visiting endemic countries and in foreign-born
patients living in Europe. In France, a retrospective analy-
sis between 2002 and 2006 in the area of Paris reported
331 patients with positive amebiasis serology. Among these
patients, 30.8% had amebic liver abscesses; 45.5% were
European-born patients [4].
For adequate clinical management, it is important to
rapidly diagnose ALA and to distinguish it from other, partic-
ularly bacterial, causes of liver abscesses. This can be challeng-
ing, as clinical and imaging findings are similar for amebic and
pyogenic liver abscesses, necrotic hepatoma or echinococcal
cyst, and therefore have poor specificity [5, 18]. Stool micros-
copy in cases of ALA is generally negative. Moreover, it is
impossible to differentiate the pathogenic species (E. histolyti-
ca) from non-pathogenic species (E. dispar or E. moshkovskii),
except if phagocytized red blood cells are present within the
trophozoite, thus confirming the diagnosis of E. histolytica.
Diagnosis of ALA is usually based on amebiasis serology even
though negative serology cases have been described [17, 20].
The combination of serological tests and PCR on a puncture
of the liver abscess offers the best diagnostic approach.
Two hypotheses can be advanced in order to explain this
liver abscess in our patient: new contamination or persistence
of endogenous abscess causing a very late relapse.
The hypothesis of recontamination cannot be excluded
although our patient had not traveled to endemic areas since
1990. The current mobility of people around the world favors
the spread of many diseases to non-endemic countries. It also
promotes the emergence of these diseases around imported
cases in persons who have not themselves traveled outside their
own country. In an early series of 152 cases of hepatic amebi-
asis in France, there were eight cases of autochthonous infec-
tion [14]. In a more recent retrospective study involving
20 patients, one case was attributed to autochthonous infec-
tion [6]. Moreover, the hypothesis of transmission by oral-anal
sex cannot be discarded even though the interview was not
conducted in this direction [7, 12].
Secondly, the assumption of asymptomatic persistence of
E. histolytica in the digestive tract for many years is to be
considered. Indeed, there is no trace of treatment by tiliqui-
nol-tilbroquinol in the patient’s medical record for his first
suspected liver abscess in 1985. Two similar cases were
recently published. In 2012, Singal et al. described a patient
living in India (an endemic area) with multiple relapses despite
treatment with metronidazole [24]. In the other article, the
authors describe a patient living in France with a recurrent
amebic abscess 10 years after the first occurrence [10]. In these
two cases, patients had not received tiliquinol-tilbroquinol.
This illustrates the importance of combination therapy with tis-
sue and contact amebicides in order to eliminate any intestinal
colonization by E. histolytica. This second hypothesis seems to
be the most likely, due to the absence of travel to an endemic
area and the low risk of acquiring the infection in France.
No drug resistance has been described to current amebici-
dal agents [3]. However, cases of relapse without travel in
endemic areas have been described in patients with adequate
amebicidal agents. Relapses of ALA are rare and have been
estimated at 0.004% of the ALA patients per year. A long
latent period may exist between the first episode of ALA and
Figure 3. Three-dimensional (3D) MRC of the patient showing no
bile duct dilatation.
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the relapse (up to 17 years in a case described by Shizuma
et al., 2000) [10, 13, 19, 21, 23, 24].
Recurrence of hepatic amebiasis 22 years after the last visit
to an endemic area is exceptional, but it should always be kept
in mind and confirmed by amebic serology and PCR in a
patient with a liver abscess, even in the absence of a recent stay
in an endemic area.
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